Last reviewed · How we verify
High-titer anti-influenza plasma
High-titer anti-influenza plasma is a Convalescent plasma Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for Acute influenza infection in hospitalized patients, Severe influenza with respiratory complications.
High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection.
High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection. Used for Acute influenza infection in hospitalized patients, Severe influenza with respiratory complications.
At a glance
| Generic name | High-titer anti-influenza plasma |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Convalescent plasma |
| Target | Influenza virus surface antigens (hemagglutinin, neuraminidase) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
This convalescent plasma product contains elevated concentrations of anti-influenza antibodies harvested from donors who have recovered from influenza infection. These antibodies directly neutralize circulating influenza virus particles and enhance immune clearance, providing immediate passive immunity to patients with acute or severe influenza. The approach leverages the donor's adaptive immune response to provide rapid therapeutic benefit without requiring the recipient's own immune system to generate antibodies.
Approved indications
- Acute influenza infection in hospitalized patients
- Severe influenza with respiratory complications
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Volume overload
- Fever
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Pilot Study for Collection of Anti-Influenza A Immune Plasma
- Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A (PHASE3)
- Blood and Plasma Collection For Use in Future Clinical Trials
- Development of Immune Globulin Treatment for Avian Flu (PHASE2)
- Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-titer anti-influenza plasma CI brief — competitive landscape report
- High-titer anti-influenza plasma updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about High-titer anti-influenza plasma
What is High-titer anti-influenza plasma?
How does High-titer anti-influenza plasma work?
What is High-titer anti-influenza plasma used for?
Who makes High-titer anti-influenza plasma?
What drug class is High-titer anti-influenza plasma in?
What development phase is High-titer anti-influenza plasma in?
What are the side effects of High-titer anti-influenza plasma?
What does High-titer anti-influenza plasma target?
Related
- Drug class: All Convalescent plasma drugs
- Target: All drugs targeting Influenza virus surface antigens (hemagglutinin, neuraminidase)
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Acute influenza infection in hospitalized patients
- Indication: Drugs for Severe influenza with respiratory complications
- Compare: High-titer anti-influenza plasma vs similar drugs
- Pricing: High-titer anti-influenza plasma cost, discount & access